Sylvester Comprehensive Cancer Center

Sylvester Presents Latest Cancer Research at ASH Annual Meeting

12.03.2015

Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine will present a selection of the latest advances in hematology research at this year’s American Society of Hematology (ASH) Annual Meeting, December 5-8, at the Orange County Convention Center in Orlando, Fla.

Reporters interested in interviewing Sylvester researchers on-site at the conference should contact Patrick Bartosch at (201) 469-6408 or patrick.bartosch@med.miami.edu.

Highlights of research presented by Sylvester researchers include:

Oral Presentations

Monday, December 7

The small molecule Img-98, a potent and selective inhibitor of the lysine demethylase Lsd-1, effectively augments the pro-differentiation effects of all-trans-retinoic acid (ATRA) in a pre-clinical model of acute myeloid leukemia (AML)
Ronan Swords; presentation #460; 7:45 a.m.; W109, Level 1

Grb2 directly interacts with HGAL and ameliorates its effects on B-cell receptor signaling
Izidore Lossos; presentation #702; 4 p.m.; W311EFGH, Level 3

Poster Presentations

Saturday, December 5

Pharmacokinetics of red cell microparticles (RMP) in rabbits and rats: effects of administration, regimen and label of assay
Wenche Jy; poster #1146; 5:30-7:30 p.m.; Hall A, Level 2

Inhibition of the PI3K/AKT/mTOR pathway leads to down regulation of c-Myc and overcomes resistance to all-trans-retinoic acid (ATRA) in acute myeloid leukemia
Ronan Swords; poster #1363; 5:30-7:30 p.m.; Hall A, Level 2

The combination of belinostat with zidovudine for treatment of HTLV-I-related adult T-cell leukemia-lymphoma
Juan Carlos Ramos; poster #1562; 5:30-7:30 p.m.; Hall A, Level 2

Sunday, December 6

A patient-specific ex vivo screening platform for personalized acute myeloid leukemia (AML) therapy
Ronan Swords; poster #1352; 5:30-7:30 p.m.; Hall A, Level 2

The BET bromodomain inhibitors EP11313 and EP11336 have potent anti-leukemic activity in acute myeloid leukemia (AML) and augment the effects of all-trans-retinoic acid (ATRA) in vitro
Ronan Swords; poster #2552; 6-8 p.m.; Hall A, Level 2

Monday, December 7

Elevated red cell microparticles (RMP) in hematologic and thrombotic disorders
Wenche Jy; poster #3553; 6-8 p.m.; Hall A, Level 2

In acute myeloid leukemia (AML), targeting the histone methyltransferase EZH2 promotes differentiation, impairs clonogenic survival and augments the anti-leukemic effects of the retinoid, all-trans-retinoic acid (ATRA)
Ronan Swords; poster #3786; 5-8 p.m.; Hall A, Level 2

FBXO10 targets HGAL for degradation
Izidore Lossos; poster #3904; 6-8 p.m.; Hall A, Level 2

Join the conversation about this year’s ASH Annual Meeting by using the hashtag #ASH2015 on Facebook, Twitter and Instagram.

E-mail a Friend